Tian Jin Heng Yi Yao Ye You Xian Gong Si

Primary objective: To investigate the in vivo pharmacokinetic characteristics of the test preparation (Betahistine Mesylate Tablets, Tianjin Hengyi Pharmaceutical Co., Ltd.) and the reference preparation (Betahistine Mesylate Tablets, trade name: Minshilan®, Eisai (China) Pharmaceutical Co., Ltd.) in healthy Chinese subjects after a single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation and the reference preparation of Betahistine Mesylate Tablets (6 mg) taken orally in healthy Chinese subjects.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of bisoprolol amlodipine tablets (specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine)) produced by Jiangsu Chengkang Pharmaceutical Co., Ltd. (holder: Tianjin Hengyi Pharmaceutical Co., Ltd.) and bisoprolol amlodipine tablets (trade name: Kangxinan®, specifications: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine)) produced by Merck Kft. under fasting/postprandial conditions in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of a single-dose oral bisoprolol amlodipine tablet test formulation (specification: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine)) and a reference formulation (trade name: Kangxinan®, specification: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine)) in healthy Chinese subjects.